Jove
Visualize
Contact Us

Related Experiment Videos

Studies on murine embryo-derived platelet-activating factor (EPAF).

L M Adamson1, B Podsiadly, Y C Smart

  • 1Department of Biological Sciences and Discipline of Surgical Science, University of Newcastle, New South Wales, Australia.

Molecular Reproduction and Development
|November 1, 1991
PubMed
Summary

Embryo-derived platelet-activating factor (EPAF) differs from synthetic platelet-activating factor (PAF). EPAF is more stable and does not aggregate platelets, suggesting it is not homologous to PAF.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence that human and equine erythrocytes could have significant roles in the transport and delivery of amino acids to organs and tissues.

Amino acids·2020
Same author

Modelling of protein turnover provides insight for metabolic demands on those specific amino acids utilised at disproportionately faster rates than other amino acids.

Amino acids·2019
Same author

Sex differences in amino acids lost via sweating could lead to differential susceptibilities to disturbances in nitrogen balance and collagen turnover.

Amino acids·2017
Same author

Diverse characteristics of the urinary excretion of amino acids in humans and the use of amino acid supplementation to reduce fatigue and sub-health in adults.

Nutrition journal·2017
Same author

The clinical relevance of alloantibody in liver transplantation.

Transplantation reviews (Orlando, Fla.)·2014
Same author

[Not Available].

Immunology today·2014
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Biochemistry
  • Immunology
  • Hematology

Background:

  • Platelet-activating factor (PAF) is a potent lipid mediator involved in various physiological and pathological processes.
  • The existence and nature of embryo-derived platelet-activating factor (EPAF) remain less understood, particularly its relationship to synthetic PAF.

Purpose of the Study:

  • To investigate the characteristics of embryo-derived platelet-activating factor (EPAF) using the splenectomized mouse bioassay (SMB).
  • To compare the properties of EPAF with synthetic platelet activating factor (PAF) and determine their relationship.

Main Methods:

  • Splenectomized mouse bioassay (SMB) to assess platelet-activating effects.
  • Platelet aggregation studies using horse platelets.
  • Thin-layer chromatography (TLC) for purification and characterization.

Related Experiment Videos

  • Plasma inactivation assays.

    • Main Results:

    • Both C16-PAF and embryo conditioned media (ECM) caused significant platelet decline in SMB at 15 min, while C18-PAF acted at 30 min.
    • EPAF activity in ECM was independent of embryo number, unlike PAF which showed linear increase with concentration.
    • EPAF was stable in mouse plasma and at high dilutions, whereas PAF activity was abolished at low dilutions and rapidly inactivated by plasma.
    • ECM and lipid-extracted ECM did not induce platelet aggregation in vitro, but purified EPAF did.

    Conclusions:

    • EPAF and synthetic PAF are not homologous molecules.
    • EPAF may involve PAF bound to a regulatory carrier molecule and is associated with inhibitory substances in ECM.
    • These findings differentiate EPAF from PAF, suggesting distinct biological roles and mechanisms.